Innocan Pharma Corp
OTC:INNPF
Income Statement
Earnings Waterfall
Innocan Pharma Corp
Income Statement
Innocan Pharma Corp
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+61%
|
0
+37%
|
0
+114%
|
1
+78%
|
1
+93%
|
3
+78%
|
4
+51%
|
7
+70%
|
10
+51%
|
14
+38%
|
19
+38%
|
24
+29%
|
29
+19%
|
29
+2%
|
30
+3%
|
29
-5%
|
27
-6%
|
|
| Gross Profit | |||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
(0)
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+55%
|
0
+39%
|
0
+50%
|
0
-8%
|
1
+247%
|
2
+263%
|
3
+64%
|
6
+76%
|
9
+53%
|
12
+29%
|
17
+39%
|
22
+32%
|
26
+19%
|
26
+0%
|
27
+4%
|
25
-7%
|
24
-6%
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
(2)
|
(3)
|
(3)
|
(4)
|
(5)
|
(4)
|
(2)
|
(3)
|
(8)
|
(7)
|
(8)
|
(8)
|
(8)
|
(9)
|
(10)
|
(14)
|
(16)
|
(20)
|
(25)
|
(27)
|
(27)
|
(27)
|
(25)
|
(25)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(3)
|
(3)
|
(4)
|
(3)
|
(1)
|
(2)
|
(6)
|
(5)
|
(6)
|
(6)
|
(7)
|
(8)
|
(9)
|
(12)
|
(14)
|
(19)
|
(23)
|
(26)
|
(26)
|
(36)
|
(34)
|
(34)
|
|
| Research & Development |
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
10
|
10
|
|
| Operating Income |
(2)
N/A
|
(3)
-80%
|
(3)
-7%
|
(4)
-20%
|
(5)
-30%
|
(4)
+8%
|
(2)
+48%
|
(3)
-20%
|
(7)
-176%
|
(7)
+9%
|
(8)
-13%
|
(7)
+7%
|
(6)
+12%
|
(6)
+9%
|
(4)
+27%
|
(4)
-4%
|
(4)
+12%
|
(4)
+1%
|
(3)
+26%
|
(1)
+56%
|
(1)
-2%
|
0
N/A
|
0
-30%
|
(1)
N/A
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
(2)
|
(0)
|
0
|
(0)
|
2
|
(0)
|
(2)
|
(3)
|
1
|
1
|
4
|
(0)
|
1
|
1
|
(0)
|
(0)
|
(0)
|
1
|
2
|
(0)
|
1
|
0
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(2)
N/A
|
(5)
-211%
|
(3)
+32%
|
(3)
-1%
|
(5)
-43%
|
(3)
+43%
|
(3)
+6%
|
(5)
-80%
|
(10)
-116%
|
(6)
+41%
|
(7)
-13%
|
(3)
+51%
|
(4)
-17%
|
(4)
-13%
|
(3)
+33%
|
(5)
-56%
|
(4)
+13%
|
(4)
+0%
|
(2)
+45%
|
0
N/A
|
1
+175%
|
2
+136%
|
1
-71%
|
(2)
N/A
|
|
| Net Income | |||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Income from Continuing Operations |
(2)
|
(5)
|
(3)
|
(3)
|
(5)
|
(3)
|
(3)
|
(5)
|
(10)
|
(6)
|
(7)
|
(3)
|
(4)
|
(4)
|
(3)
|
(5)
|
(4)
|
(4)
|
(3)
|
(1)
|
(0)
|
1
|
(0)
|
(2)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
|
| Net Income (Common) |
(2)
N/A
|
(5)
-211%
|
(3)
+32%
|
(3)
-1%
|
(5)
-43%
|
(3)
+43%
|
(3)
+6%
|
(5)
-79%
|
(10)
-116%
|
(6)
+41%
|
(7)
-12%
|
(3)
+52%
|
(4)
-20%
|
(4)
-16%
|
(3)
+28%
|
(5)
-59%
|
(5)
+6%
|
(5)
-11%
|
(4)
+16%
|
(3)
+40%
|
(2)
+30%
|
(1)
+65%
|
(2)
-143%
|
(3)
-105%
|
|
| EPS (Diluted) |
-0.71
N/A
|
-2.85
-301%
|
-1.79
+37%
|
-1.52
+15%
|
-2.06
-36%
|
-1.01
+51%
|
-0.76
+25%
|
-1.32
-74%
|
-2.9
-120%
|
-1.53
+47%
|
-1.72
-12%
|
-0.81
+53%
|
-0.98
-21%
|
-1.13
-15%
|
-0.81
+28%
|
-1.26
-56%
|
-1.19
+6%
|
-1.25
-5%
|
-1
+20%
|
-0.6
+40%
|
-0.43
+28%
|
-0.16
+63%
|
-0.35
-119%
|
-0.72
-106%
|
|